An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex
Nucleic Acids Research · 09.02.2024 · 52 (3) · 1325-1340
DOI: 10.1093/nar/gkad1194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 14.12.2023. Verfasst von Ashleigh Shannon und 11 weiteren Autor:innen. Beteiligte Einrichtung: AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288, Marseille Cedex 09, France. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, Polyphosphates, SARS-CoV-2. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation pour la Recherche Médicale, H2020 SC1-PHE-Coronavirus-2020, Innovative Medicines Initiative.
Abstract (Originalsprache)
Nucleotide analogues (NA) are currently employed for treatment of several viral diseases, including COVID-19. NA prodrugs are intracellularly activated to the 5′-triphosphate form. They are incorporated into the viral RNA by the viral polymerase (SARS-CoV-2 nsp12), terminating or corrupting RNA synthesis. For Coronaviruses, natural resistance to NAs is provided by a viral 3′-to-5′ exonuclease heterodimer nsp14/nsp10, which can remove terminal analogues. Here, we show that the replacement of the α-phosphate of Bemnifosbuvir 5′-triphosphate form (AT-9010) by an α-thiophosphate renders it resistant to excision. The resulting α-thiotriphosphate, AT-9052, exists as two epimers (RP/SP). Through co-crystallization and activity assays, we show that the Sp isomer is preferentially used as a substrate by nucleotide diphosphate kinase (NDPK), and by SARS-CoV-2 nsp12, where its incorporation causes immediate chain-termination. The same -Sp isomer, once incorporated by nsp12, is also totally resistant to the excision by nsp10/nsp14 complex. However, unlike AT-9010, AT-9052-RP/SP no longer inhibits the N-terminal nucleotidylation domain of nsp12. We conclude that AT-9052-Sp exhibits a unique mechanism of action against SARS-CoV-2. Moreover, the thio modification provides a general approach to rescue existing NAs whose activity is hampered by coronavirus proofreading capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288, Marseille Cedex 09, France.
- ATEA Pharmaceuticals, Inc., 225 Franklin St., Suite 2100, Boston, MA 02110, USA.
- European Virus Bioinformatics Center, Leutragraben 1, 07743 Jena, Germany.
ORCID-Profile: Ashleigh Shannon, Mikael Feracci, François Ferron, Bruno Canard
Förderung
- Fondation pour la Recherche Médicale
- H2020 SC1-PHE-Coronavirus-2020
- Innovative Medicines Initiative
- French Infrastructure for Integrated Structural Biology
Zitieren
APA
Shannon, A., Chazot, A., Feracci, M., Falcou, C., Fattorini, V., Selisko, B., Good, S., Moussa, A., Sommadossi, J. P., Ferron, F., Alvarez, K., & Canard, B. (2024). An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex. Nucleic Acids Research, 52(3), 1325-1340. https://doi.org/10.1093/nar/gkad1194
Vancouver
Shannon A, Chazot A, Feracci M, Falcou C, Fattorini V, Selisko B, et al. An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex. Nucleic Acids Research. 2024;52(3):1325-1340. doi:10.1093/nar/gkad1194
BibTeX
@article{Shannon2024,
author = {Shannon, Ashleigh and Chazot, Aurélie and Feracci, Mikael and Falcou, Camille and Fattorini, Véronique and Selisko, Barbara and Good, Steven and Moussa, Adel and Sommadossi, Jean-Pierre and Ferron, François and Alvarez, Karine and Canard, Bruno},
title = {An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {3},
pages = {1325--1340},
doi = {10.1093/nar/gkad1194}
}
EUVIMED